How would you treat a patient with BRAF mutated Metastatic Melanoma who has progressed on targeted therapy (Encorafenib + Binimetinib) and Immuotherapy (Nivolumab/Ipilimumab), but yet maintain an excellent performance status?

Agree that clinical trial access would be ideal. If unable to access for any reason or to "bridge" if the patient is symptomatic, one might consider re-treatment with BRAF/MEK inhibitor based on phase II and retrospective data demonstrating response (Schreuer et al.: Combination of dabrafenib plus t...

This is a challenging situation as the patient has received all standard of care options. If there is a possibility for the patient to be referred to a site with clinical trial options that would be ideal. Outside of a clinical trial the standard of care options for therapy, such as cytoxic chemothe...